FREQUENCY THERAPEUTICS INC (FREQ)
US35803L1089 - Common Stock
Taking everything into account, FREQ scores 2 out of 10 in our fundamental rating. FREQ was compared to 587 industry peers in the Biotechnology industry. FREQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FREQ is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year FREQ has reported negative net income.
In the past year FREQ has reported a negative cash flow from operations.
FREQ had negative earnings in each of the past 5 years.
In the past 5 years FREQ reported 4 times negative operating cash flow.
1.2 Ratios
FREQ has a Return On Assets of -76.59%. This is in the lower half of the industry: FREQ underperforms 70.30% of its industry peers.
Looking at the Return On Equity, with a value of -145.99%, FREQ is doing worse than 68.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.59% | ||
| ROE | -145.99% | ||
| ROIC | N/A |
ROA(3y)-41%
ROA(5y)-34.99%
ROE(3y)-65.47%
ROE(5y)-52.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for FREQ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FREQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
FREQ has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FREQ has more shares outstanding
FREQ has a worse debt/assets ratio than last year.
2.2 Solvency
FREQ has an Altman-Z score of -5.79. This is a bad value and indicates that FREQ is not financially healthy and even has some risk of bankruptcy.
FREQ has a Altman-Z score of -5.79. This is in the lower half of the industry: FREQ underperforms 68.98% of its industry peers.
FREQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.79 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 3.14 indicates that FREQ has no problem at all paying its short term obligations.
FREQ's Current ratio of 3.14 is on the low side compared to the rest of the industry. FREQ is outperformed by 68.48% of its industry peers.
FREQ has a Quick Ratio of 3.14. This indicates that FREQ is financially healthy and has no problem in meeting its short term obligations.
FREQ's Quick ratio of 3.14 is on the low side compared to the rest of the industry. FREQ is outperformed by 67.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.14 |
3. Growth
3.1 Past
FREQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.39%, which is quite good.
The Revenue for FREQ has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q17.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
FREQ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.85%
EPS Next 2Y22.39%
EPS Next 3Y13.2%
EPS Next 5Y9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
FREQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FREQ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FREQ's earnings are expected to grow with 13.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.39%
EPS Next 3Y13.2%
5. Dividend
5.1 Amount
FREQ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FREQUENCY THERAPEUTICS INC
NASDAQ:FREQ (11/3/2023, 8:00:00 PM)
0.2996
+0.02 (+5.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.59% | ||
| ROE | -145.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)13.39%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y